The National Assembly has passed a motion that could soon allow Kenya to produce vaccines through the International Vaccine Institute (IVI).
This comes after the House adopted a report of the Departmental Committee on Health on its consideration of the agreement on the establishment of the IVI, a move that will facilitate Kenya’s integration into a network of vaccine producers, consortia, and health researchers.
Moving the motion on the report, Endebess MP Robert Pukose, who chairs the departmental committee on health, said Kenya will greatly benefit from IVI membership as it will enable knowledge transfer, capacity building in biotechnology and vaccine production.
“This is crucial as vaccine research, development and field research are catalysts to the attainment of Universal Health Coverage (UHC),” said Pukose.
He stressed the importance of technical and hands-on training across vaccine development and production processes, disease surveillance, biopharmaceutical manufacturing, biosafety, and good manufacturing practices.
Pukose noted that Kenya’s membership in IVI would promote knowledge transfer, enabling self-sufficiency by positioning Kenya as a vaccine producer in the region. The move would also benefit Kenya, and create revenue streams by supplying vaccines to neighboring countries.
“We must be in the forefront in having our own institute, Biovax, that can manufacture for us our own vaccines, not just for outbreaks, but also for infectious diseases and, more so, among the children,” he said.
The Endebess MP emphasized Kenya’s existing capability in vaccine production for animals through the Kenya Veterinary Vaccines Production Institute (KEVEVAPI), indicating vaccine production is not a new phenomenon for Kenya.
In supporting IVI membership, Pukose underscored its critical role in supporting the functions of Kenya Biovax Institute (KBI) and the Kenya Medical Research Institute (KEMRI), two Semi-Autonomous Government Agencies (SAGAs) under the Ministry of Health.
“KEMRI is involved in research and the Kenya Biovax Institute is involved in production and marketing of vaccines. In recognition of this, the KBI and KEMRI shall enter into a strategic collaborative partnership in technology transfer and manufacturing support,” he said.
Currently, the IVI supports the KBI as it seeks to establish itself in bio manufacturing of human vaccines.
Email your news TIPS to Editor@nairobilawmonthly.com, and to advertise with us, call +254715061658 anytime of the day
